Syneos Health Inc (SYNH) Position Decreased by Mesirow Financial Investment Management Equity Management

Mesirow Financial Investment Management Equity Management decreased its stake in Syneos Health Inc (NASDAQ:SYNH) by 24.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 225,200 shares of the company’s stock after selling 71,060 shares during the quarter. Mesirow Financial Investment Management Equity Management owned 0.22% of Syneos Health worth $8,862,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in SYNH. JPMorgan Chase & Co. boosted its position in shares of Syneos Health by 1,589.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,319,875 shares of the company’s stock valued at $68,040,000 after purchasing an additional 1,241,754 shares during the period. BlackRock Inc. boosted its position in shares of Syneos Health by 10.3% in the 3rd quarter. BlackRock Inc. now owns 8,035,926 shares of the company’s stock valued at $414,252,000 after purchasing an additional 751,050 shares during the period. Vanguard Group Inc boosted its position in shares of Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after purchasing an additional 624,991 shares during the period. Vanguard Group Inc. boosted its position in shares of Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc. now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after purchasing an additional 624,991 shares during the period. Finally, Thrivent Financial for Lutherans boosted its position in shares of Syneos Health by 3,641.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 473,191 shares of the company’s stock valued at $24,393,000 after purchasing an additional 460,545 shares during the period.

In other news, CEO Alistair Macdonald sold 6,697 shares of the firm’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $53.04, for a total transaction of $355,208.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jonathan Olefson purchased 750 shares of the business’s stock in a transaction dated Monday, December 17th. The shares were purchased at an average cost of $41.27 per share, with a total value of $30,952.50. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

SYNH opened at $51.02 on Monday. Syneos Health Inc has a fifty-two week low of $31.10 and a fifty-two week high of $53.95. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.97 and a quick ratio of 0.97. The stock has a market cap of $5.23 billion, a PE ratio of 26.30, a PEG ratio of 1.42 and a beta of 1.51.

A number of equities research analysts have commented on SYNH shares. William Blair upgraded Syneos Health from a “market perform” rating to an “outperform” rating in a research report on Friday, October 19th. Zacks Investment Research upgraded Syneos Health from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Tuesday, December 4th. Barclays decreased their price objective on Syneos Health from $51.00 to $45.00 and set an “equal weight” rating for the company in a research report on Thursday, January 3rd. Robert W. Baird set a $60.00 price objective on Syneos Health and gave the stock a “buy” rating in a research report on Tuesday, January 8th. Finally, ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $53.44.

WARNING: “Syneos Health Inc (SYNH) Position Decreased by Mesirow Financial Investment Management Equity Management” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2019/02/11/syneos-health-inc-synh-position-decreased-by-mesirow-financial-investment-management-equity-management.html.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Featured Story: What is an SEC Filing?

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply